

The Tempus Report

At Tempus we offer a report for each patient that highlights key findings, including potentially actionable alterations, immunotherapy markers and clinical trial options that can help inform patient care.

GENOMIC VARIANTS

Clinically relevant somatic alterations, incidental germline findings, and pertinent negatives.¹

1 Somatic Classification

Potentially Actionable **BRCA2**

A somatic alteration that has a functional significance or association with the disease state and has associated therapeutic, prognostic or diagnostic evidence.

Biologically Relevant **TSC2**

A protein-altering somatic alteration that may have functional significance or may have been observed in the medical literature but is not associated with a specific therapy in the Tempus knowledge database.

2 Germline Classification²

Pathogenic and likely pathogenic incidental germline variants are reported when a normal sample is provided.³ These are variants that are associated with inherited cancer syndromes, based on ACMG recommendations, NCCN guidelines and other published literature.

Prostate Sample
Patient 22112

Diagnosis
**Metastatic prostatic
adenocarcinoma**

Accession No.
Prostate 22112

xT

Date of Birth
xx/xx/1948

Sex
Male

Physician
Dr. Bob

Institution
**Chicago Cancer Center
123456789**

TEMPUS | xT
648 gene panel

Tumor specimen:
Chest wall, left
Collected xx/xx/2022
Received xx/xx/2022
Tumor Percentage: 50%

Normal specimen:
Blood
Collected xx/xx/2022
Received xx/xx/2022

Notes
This patient has a reportable germline variant in BRCA2. Additionally, a somatic pathogenic variant was identified in BRCA2. Confirmatory germline testing and genetic counseling are recommended. For additional detail, please see the Somatic Variant Details and Germline Variant Details sections of this report.

GENOMIC VARIANTS

1 Somatic - Potentially Actionable Variant Allele Fraction

BRCA2 p.R2659fs Frameshift - LOF 71.0%

Somatic - Biologically Relevant

TSC2 c.1120-1G>A Splice region variant - LOF 27.5%

2 Germline - Pathogenic / Likely Pathogenic Clinical Signi³ cance

BRCA2 p.S871* chr13:32911104 * Pathogenic
Hereditary breast and
ovarian cancer, Fanconi
anemia

IMMUNOTHERAPY MARKERS

Tumor Mutational Burden	Microsatellite Instability Status
5.3 m/MB 65th percentile	Stable Equivocal High

FDA-APPROVED THERAPIES, CURRENT DIAGNOSIS

PARP Inhibitor	Olaparib	<ul style="list-style-type: none"> NCCN, Consensus, Prostate Cancer MSK OncoKB, Level 1 BRCA2 p.R2659fs Loss-of-function
	Rucaparib	<ul style="list-style-type: none"> NCCN, Consensus, Prostate Cancer MSK OncoKB, Level 1 BRCA2 p.R2659fs Loss-of-function
		<ul style="list-style-type: none"> NCCN, Consensus, Prostate Cancer BRCA2 p.S871* Loss-of-function GERMLINE

TEMPUS Electronically Signed By Lab Director, MD CLIA Number 14D2114007 Date Signed/Reported xx/xx/2022 Laboratory Medical Director Lab Director, MD Tempus ID # Prostate 22112 Pipeline Version 3.10.0 1/7

Tempus Labs, Inc • 600 West Chicago Avenue, Ste 510 • Chicago, IL • 60654 • tempus.com • support@tempus.com

¹ Select cancer types display disease associated genes for which no alterations were identified in the specimen that was tested.

² Tempus xT is not a validated germline panel. The incidental germline findings are reported in a limited set of genes when sequencing a normal match specimen. Confirmatory germline testing with an appropriate test may be recommended for further evaluation, if clinically indicated.

³ Certain states require a signed patient consent to release germline results.

3 IMMUNOTHERAPY MARKERS

Key decision drivers for immunotherapy identified by our proprietary sequencing technologies and molecular profiling.

Tumor Mutational Burden (TMB)

A measurement of the quantity of mutations carried by a tumor. TMB is calculated as the number of all protein-altering (non-synonymous) mutations per million base pairs of DNA covered by the Tempus panel. A TMB of ≥ 10 m/Mb is designated as TMB-high.

Microsatellite Instability (MSI)

A reference for the amount of genomic instability that results from impaired DNA mismatch repair (MMR) activity. A high level of microsatellite instability is noted as MSI-High.

Immunohistochemistry (IHC)

Tempus offers four (4) different PD-L1 IHC clones to assess PD-L1 expression, as well as a DNA mismatch repair (MMR) IHC panel.

4 FDA-APPROVED THERAPIES

FDA-approved therapies organized by level of evidence with associated NCCN and MSK OncoKB tags, highlighting response or resistance evidence.

Tempus also designates previously prescribed therapies in gray italic font, based on the clinical documents received (smart therapies).

5 CLINICAL TRIALS

A select list of clinical trials matched to genomic features, cancer type, clinical history, and distance from the patient's point-of-care.

LOW COVERAGE REGIONS

Low Coverage Regions are included when mean coverage over any region(s) of a gene falls below a threshold of 35x in the tumor sample. The absence of alterations in genes with low coverage should be interpreted carefully in the context of the patient's diagnosis with consideration for retesting.

6 VARIANTS OF UNKNOWN SIGNIFICANCE

DNA alterations identified with weak or ambiguous evidence of relevance to cancer biology.

Prostate Sample Patient 22112

Diagnosis
Metastatic prostatic adenocarcinoma

Accession No.
Prostate 22112

XT

Date of Birth
xx/xx/1948
 Sex
Male
 Physician
Dr. Bob
 Institution
**Chicago Cancer Center
 123456789**

GENOMIC VARIANTS

Somatic - Potentially Actionable

BRCA2

 p.R2659fs Frameshift - LOF

Variant Allele Fraction
 71.0%

Somatic - Biologically Relevant

TSC2

 c.1120-1G>A Splice region variant - LOF

Germline - Pathogenic / Likely Pathogenic

BRCA2

 p.S871* chr13:32911104

Clinical Significance
 Pathogenic
 Hereditary breast and ovarian cancer, Fanconi anemia

TEMPUS xT
 648 gene panel
 Tumor specimen:
 Chest wall, left
 Collected xx/xx/2022
 Received xx/xx/2022
 Tumor Percentage: 50%
 Normal specimen:
 Blood
 Collected xx/xx/2022
 Received xx/xx/2022

IMMUNOTHERAPY MARKERS

Tumor Mutational Burden

5.3 m/Mb

 65th percentile

Microsatellite Instability Status

Stable

Equivalocal

High

FDA-APPROVED THERAPIES, CURRENT DIAGNOSIS

PARP Inhibitor	Olaparib	<div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">NCCN, Consensus, Prostate Cancer</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">MSK OncoKB, Level 1</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.R2659fs Loss-of-function</div>
		<div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">NCCN, Consensus, Prostate Cancer</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.S871* Loss-of-function</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px; background-color: #6c757d; color: white; font-size: 0.7em;">GERMLINE</div>
	Rucaparib	<div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">NCCN, Consensus, Prostate Cancer</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">MSK OncoKB, Level 1</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.R2659fs Loss-of-function</div>
		<div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">NCCN, Consensus, Prostate Cancer</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.S871* Loss-of-function</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px; background-color: #6c757d; color: white; font-size: 0.7em;">GERMLINE</div>

TEMPUS Electronically Signed By Lab Director, MD CLIA Number 14D2114007 Date Signed/Reported xx/xx/2022 Laboratory Medical Director Lab Director, MD Tempus ID # Prostate 22112 Pipeline Version 3.10.0 1/7
Tempus Labs, Inc • 600 West Chicago Avenue, Ste 510 • Chicago, IL • 60654 • tempus.com • support@tempus.com

7 SOMATIC AND GERMLINE VARIANT DETAILS

Additional clinical context for reported somatic and germline variants that are classified as pathogenic or likely pathogenic.

Prostate Sample Patient 22112

Somatic	Mutation effect	Variant allele fraction
RSF1	c.2459A>G p.K820R Missense variant NM_016578	21.6% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 21.6%, gray 21.6%);"></div>
PIK3C2B	c.1034+5G>T Splice region variant NM_002646	20.7% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 20.7%, gray 20.7%);"></div>
PRKDC	c.2900C>G p.P967R Missense variant NM_006904	19.4% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 19.4%, gray 19.4%);"></div>
NSD2	c.185T>C p.M62T Missense variant NM_133331	18.6% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 18.6%, gray 18.6%);"></div>
BCR	c.3457+4A>T Splice region variant NM_004327	17.2% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 17.2%, gray 17.2%);"></div>
RNF139	c.1391T>G p.V464G Missense variant NM_007218	16.7% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 16.7%, gray 16.7%);"></div>
CALR	c.1108G>C p.E370Q Missense variant NM_004343	15.5% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 15.5%, gray 15.5%);"></div>

SOMATIC VARIANT DETAILS - POTENTIALLY ACTIONABLE

BRCA2

 c.7975del p.R2659fs NM_000059 Frameshift - LOF

VAF: 71.0%

BRCA2 encodes a nuclear phosphoprotein which helps maintain DNA stability through homologous recombination based DNA double stranded break repair and involvement in DNA damage checkpoint control. Loss of function mutations and copy number loss of BRCA2 are associated with cancer progression.

SOMATIC VARIANT DETAILS - BIOLOGICALLY RELEVANT

TSC2

 c.1120-1G>A NM_000548 Splice region variant - LOF

VAF: 27.5%

TSC2 encodes a protein, tuberin, that interacts with the protein encoded by TSC1, hamartin. These proteins are involved in the regulation of the PI3K-AKT-mTOR pathway, a pathway involved in cell proliferation and survival. Loss of function mutations and copy number loss of TSC2 are associated with cancer progression.

GERMLINE VARIANT DETAILS

BRCA2

 c.2612C>A p.S871* NM_000059 chr13:32911104 Stop gain

Clinical Significance: Pathogenic

BRCA2 encodes a nuclear phosphoprotein which helps maintain DNA stability through homologous recombination based DNA double stranded break repair and involvement in DNA damage checkpoint control. Germline pathogenic variants in BRCA2 have been associated with autosomal dominant hereditary breast and ovarian cancer syndrome, which results in an increased risk of breast, ovarian, and fallopian tube cancers in women. Men with pathogenic variants in BRCA2 are at an increased risk to develop breast and prostate cancer, and both men and women are at an increased risk to develop pancreatic cancer (PMID: 33406487). Additionally, BRCA2 is associated with the autosomal recessive condition Fanconi anemia; heterozygotes are considered carriers, while homozygotes or compound heterozygotes are likely to be affected (PMID: 15070707). Clinical correlation, including confirmation of this variant through a validated germline assay, and genetic counseling are recommended for this patient and any potentially at-risk family members.

TEMPUS Electronically Signed By Lab Director, MD CLIA Number 14D2114007 Date Signed/Reported xx/xx/2022 Laboratory Medical Director Lab Director, MD Tempus ID # Prostate 22112 Pipeline Version 3.10.0 3/7
Tempus Labs, Inc • 600 West Chicago Avenue, Ste 510 • Chicago, IL • 60654 • tempus.com • support@tempus.com

8 CLINICAL HISTORY

A timeline of the patient's clinical history including past procedures and treatments, informing reported smart therapy implications.

Prostate Sample Patient 22112

FDA-APPROVED THERAPIES, OTHER INDICATIONS

PARP Inhibitor	Niraparib	<div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">NCCN, Consensus, Ovarian Cancer</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.R2659fs Loss-of-function</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.S871* Loss-of-function</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px; background-color: #6c757d; color: white; font-size: 0.7em;">GERMLINE</div>
	Talazoparib	<div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">NCCN, Consensus, Breast Cancer</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.R2659fs Loss-of-function</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.S871* Loss-of-function</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px; background-color: #6c757d; color: white; font-size: 0.7em;">GERMLINE</div>
Combination (PARP Inhibitor + Anti-VEGF MAb)	Olaparib + Bevacizumab	<div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">NCCN, Consensus, Ovarian Cancer</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.R2659fs Loss-of-function</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px;">BRCA2 p.S871* Loss-of-function</div> <div style="border: 1px solid gray; border-radius: 5px; padding: 2px; margin-bottom: 5px; background-color: #6c757d; color: white; font-size: 0.7em;">GERMLINE</div>

None of the therapies on this report were identified in the clinical notes received and abstracted by Tempus, which may not reflect the complete treatment history.

CLINICAL TRIALS

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (NCT04497844)	Phase III City, State - x mi ✓ BRCA2 mutation ✓ BRCA2 mutation
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1 or TSC2 Genes (PRECISION 1) (NCT05103358)	Phase II City, State - x mi ✓ TSC2 mutation
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535)	Phase I City, State - x mi ✓ TSC2 mutation ✓ BRCA2 mutation ✓ BRCA2 mutation

VARIANTS OF UNKNOWN SIGNIFICANCE

Somatic	Mutation effect	Variant allele fraction
HSP90AA1	c.704C>G p.S235C Missense variant NM_001017963	43.5% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 43.5%, gray 43.5%);"></div>
KAT6A	c.2926G>A p.G976S Missense variant NM_006766	29.8% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 29.8%, gray 29.8%);"></div>
APOB	c.8504_8567del p.L2835fs Frameshift NM_000384	29.0% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 29.0%, gray 29.0%);"></div>
C1TA	c.579C>A p.N193K Missense variant NM_001286402	28.1% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 28.1%, gray 28.1%);"></div>
CCNE1	c.610-1G>T Splice region variant NM_001238	28.0% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 28.0%, gray 28.0%);"></div>
CCDC6	c.712C>T p.P238S Missense variant NM_005436	23.4% <div style="width: 100%; height: 5px; background: linear-gradient(to right, black 23.4%, gray 23.4%);"></div>

TEMPUS Electronically Signed By Lab Director, MD CLIA Number 14D2114007 Date Signed/Reported xx/xx/2022 Laboratory Medical Director Lab Director, MD Tempus ID # Prostate 22112 Pipeline Version 3.10.0 2/7
Tempus Labs, Inc • 600 West Chicago Avenue, Ste 510 • Chicago, IL • 60654 • tempus.com • support@tempus.com

CLINICAL HISTORY

Prostate Sample Patient 22112

DIAGNOSIS
 Diagnosed on xx/xx/2017

RADIO THERAPY
 Radiotherapy
 Began xx/xx/2017 - Ended xx/xx/2017

THERAPIES
Cabazitaxel
 Began xx/xx/2021 - Ended xx/xx/2022

Docetaxel
 Began xx/xx/2021 - Ended xx/xx/2021

Enzalutamide
 Began xx/2020 - Ended xx/xx/2021

Abiraterone
 Began xx/xx/2017 - Ended xx/xx/2020

Leuprolide
 Began xx/xx/2017 - Ended unknown

Assay Description

The Tempus xT(version 4) assay is a custom oncology testing panel consisting of 648 genes with single nucleotide variants, indels and translocations measured by hybrid capture next-generation sequencing (NGS). A complete gene list can be found at the end of this assay description. This assay has 98.2% sensitivity for single nucleotide variants (SNV) above 5% variant allele fraction (VAF), 91.8% sensitivity for indels above 5% VAF and 91.7% sensitivity for reported translocations. The assay has 91.3% sensitivity for copy number alterations for samples with the copy number gain limit of detection (LOD) set as 30% tumor purity and copy number loss at 40% tumor purity. (Certain driver or resistance genes may be reported to lower VAFs when technically possible.)

Potentially Actionable alterations are protein-altering variants with an associated therapy based on evidence from the medical literature. **Biologically Relevant** alterations are protein-altering variants that may have functional significance or have been observed in the medical literature but are not associated with a specific therapy in the Tempus knowledge database. **Variants of Unknown Significance (VUS)** are protein-altering variants exhibiting an unclear effect on function and/or without sufficient evidence to determine their pathogenicity. **Benign variants** are not reported. **Low Coverage Regions** are included when mean coverage over any region(s) of a gene falls below a threshold of 35x in the tumor sample. The absence of alterations in genes with low coverage should be interpreted carefully in the context of the patient's diagnosis with consideration for retesting. Variants are identified through aligning the patient's DNA sequence to the human genome reference sequence version hg19 (GRCh37). The clinical summary (first page of the report) shows actionable and biologically relevant somatic variants, and certain pathogenic or likely pathogenic inherited variants that are reported as incidental findings (if a matched normal sample was provided and analyzed). Reportable secondary/incidental findings are limited to genes and variants associated with inherited cancer syndromes.

Tumor mutational burden (TMB) measures the quantity of somatic SNVs and indels, of any pathogenicity, including benign, carried in a tumor as the number of protein-altering mutations per million coding base pairs. TMB is calculated at the time of initial report delivery. Accordingly, the TMB calculation is based upon (a) both the tumor and normal sample if Tempus had analyzed both at the time of the initial report, or (b) the tumor sample only if no normal sample had been analyzed at the time of the initial report. Please note that tumor only calculations are not updated or amended even if a normal sample is subsequently analyzed. Studies have shown that tumors with higher TMB have an increased likelihood of response to immunotherapy [1, 2].

TEMPUS Electronically Signed By Lab Director, MD CLIA Number 14D2114007 Date Signed/Reported xx/xx/2022 Laboratory Medical Director Lab Director, MD Tempus ID # Prostate 22112 Pipeline Version 3.10.0 4/7
Tempus Labs, Inc • 600 West Chicago Avenue, Ste 510 • Chicago, IL • 60654 • tempus.com • support@tempus.com

Report Glossary

Genomic Variants

Mutations

A change in the DNA sequence of a gene, which can be a somatic (acquired) or a germline (inherited) event. For each somatic mutation, Tempus provides a Variant Allele Fraction (VAF), which is the proportion of sequencing reads from the sample that contain the mutation of interest.

Copy Number Variations (CNV)

A deviation from the normal number of copies of a gene, which is typically 2. They are reported either as a Copy Number Gain (amplification) or a Copy Number Loss (deletion).

A Copy Number Gain is reported when ≥ 8 copies are detected, and a Copy Number Loss is reported when 2 copies are lost.

Loss of Heterozygosity (LOH)

Loss of Heterozygosity (LOH) occurs when there is loss of the second, wild-type copy of a gene that already has an inactivating alteration in the first copy. When LOH is detected for germline BRCA1 and BRCA2 variants, it is displayed as a copy number loss on the report, and the gene description for the copy number loss will note that somatic LOH was identified.

Chromosomal Rearrangements (Translocations)

A change to the structure of a chromosome, such as a deletion, duplication, inversion or translocation. Chromosomal rearrangements can bring two distant gene fragments together to form fusion genes. This may result in expression of a fusion protein with new or enhanced function that contributes to tumorigenesis.

Tempus detects rearrangements (translocations) through two lines of sequencing: DNA sequencing for a subset of genes, and unbiased fusion transcript detection using whole transcriptome RNA sequencing.

Variant Details

Missense Variant

A genetic alteration in which a single base pair substitution alters the genetic code in a way that produces a different amino acid from the usual amino acid at that position in the protein. Some missense variants will alter the function of the protein.

Frameshift

Small insertion or deletion of a DNA sequence in the coding region of a gene that changes the reading frame of the protein and disrupts subsequent amino acid sequence. Typically results in a non-functional protein.

Stop Gain

DNA sequence change that causes a premature stop in the amino acid sequence of the protein. Typically results in a truncated, non-functional protein.

Splice Region Variant

DNA sequence change that results in exons of the gene being incorrectly spliced (or pasted) together, often with the result that an exon is excluded.

Gain-of-Function (GOF)

A DNA sequence change that results in a protein which has either increased or novel function.

Loss-of-Function (LOF)

A DNA sequence change that results in a protein which loses normal function.

c.; p.

Designates a variant's effect at the nucleotide/mRNA level; at the amino acid/protein level.

NM_#

The RefSeq transcript number for the c. alteration.

Learn more

tempus.com/oncology/ 